LONDON, April 7, 2014 /PRNewswire/ --
On Friday, April 04, 2014, the
NASDAQ Composite ended at 4,127.73, down 2.60%, the Dow Jones
Industrial Average declined 0.96% to 16,412.71, and the S&P 500
closed at 1,865.09, down 1.25%. The losses were broad based as nine
out of 10 sectors ended the session in negative. The S&P 500
Health Care Sector Index finished the day at 671.79, down 1.54%,
and has fallen by 2.23% in the last one month. Investor-Edge has
initiated coverage on the following equities: Merck & Co. Inc.
(NYSE: MRK), Bristol-Myers Squibb Co. (NYSE: BMY), Johnson &
Johnson (NYSE: JNJ) and Eli Lilly & Co. (NYSE: LLY). Free
technical research on MRK, BMY, JNJ and LLY can be downloaded upon
signing up at:
http://www.investor-edge.com/843-register
Merck & Co. Inc.'s stock fell 0.16% on Friday, closing at
$56.12, after oscillating between
$56.09 and $56.72. A total of 10.41
million shares were traded, which is below its three months average
volume of 12.81 million shares. Merck & Co. Inc.'s shares have
surged 12.83% in the previous three months and 12.13% on YTD basis.
The company's stock is trading above its 50-day and 200-day moving
averages. Merck & Co. Inc.'s 50-day moving average of
$55.39 is above its 200-day moving
average of $49.95. Furthermore, the
company's stock is trading at a PE ratio of 16.13 and has a
Relative Strength Index (RSI) of 52.45. Sign up today to read free
research on MRK at:
http://www.investor-edge.com/843-MRK-07Apr2014.pdf
Shares in Bristol-Myers Squibb Co. witnessed a trading volume of
8.44 million shares on Friday, as compared with its three months
average volume of 9.41 million shares. The stock ended the day at
an intra-day low of $49.89, down
1.93%, after trading between $49.89
and $51.71. Shares in Bristol-Myers
Squibb Co. have lost 10.21% in the last one month and 6.13% on YTD
basis. The stock is trading above its 200-day moving average.
Bristol-Myers Squibb Co.'s 50-day moving average of $52.74 is above its 200-day moving average of
$49.19. Additionally, the company's
shares are trading at a PE ratio of 29.74 and have an RSI of 32.24.
Sign up today to read free research on BMY at:
http://www.investor-edge.com/843-BMY-07Apr2014.pdf
On Friday, shares in Johnson & Johnson gained 0.16% finishing
the session at $98.42, after hitting
a new 52-week high of $99.38. The
stock recorded a trading volume of 10.31 million shares which is
above its three months average volume of $8.83 million shares. The stock fluctuated
between $98.32 and $99.38 during the
session. Johnson & Johnson's shares have advanced 5.95% in the
last one month, 6.60% in the previous three months, and 7.46% on
YTD basis. The stock is trading above its 50-day and 200-day moving
averages. Johnson & Johnson's 50-day moving average of
$92.81 is above its 200-day moving
average of $91.42. Moreover, the
company's shares are trading at a PE ratio of 17.92 and have RSI of
72.00. Sign up today to read free research on JNJ at:
http://www.investor-edge.com/843-JNJ-07Apr2014.pdf
Eli Lilly & Co.'s stock recorded a trading volume of 5.18
million shares, as compared with its three months average volume of
5.73 million shares. The stock ended Friday's session at
$59.01, up 0.07%, and at an intraday
trading range of $58.93 and
$59.96. Eli Lilly & Co.'s shares
have gained 0.49% in the last one month, 14.52% in the previous
three months, and 15.71% on YTD basis. The stock is trading above
its 50-day and 200-day moving averages. Eli Lilly & Co.'s
50-day moving average of $56.93 is
above its 200-day moving average of $52.71. Further, the company's shares are trading
at a PE ratio of 13.35 and have an RSI of 59.08. Sign up today to
read free research on LLY at:
http://www.investor-edge.com/843-LLY-07Apr2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge